Pam2-ODN protects against pneumonia in the presence of human AML. (A) Viability of human AML cell lines 72 hours after the indicated treatments, assessed by XTT conversion (top), trypan blue exclusion (middle), and hemacytometer counts (bottom). (B) Influence of Pam2-ODN on BrdU staining in human AML cell lines. (C) Trypan blue exclusion of primary human AML cells following the indicated treatments. (D) Trypan blue exclusion of primary human AML cells 72 hours after the indicated treatments. (E) Circulating human AML cells in engrafted NSG mice following treatment with Pam2-ODN or PBS. (F) Survival of primary human AML-engrafted NSG mice after P. aeruginosa infection (10 mL of 9 × 109 CFU/mL) following treatment with Pam2-ODN or PBS. (G) Bacterial burdens of lungs harvested immediately after infection in F. (H) Bacterial burdens of the indicated organs at the time of death of mice from F. *P < .05 vs PBS treated, **P < .005 vs PBS treated.
